Drugs / BLX-0871
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07140081 | Sep 2025 → Apr 2026 overdue | — | Biolexis Therapeutics | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BLX-0871 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07140081 ↗ |
| Action | Activate | “activating AMP-activated protein kinase (AMPK)” NCT07140081 ↗ |
| Modality | Small molecule | “BLX-0871, a novel oral small-molecule AMPK activator” NCT07140081 ↗ |
| Route | Oral | “BLX-0871 Single or Multiple doses administered orally as a tablet” NCT07140081 ↗ |